Results 101 to 110 of about 11,033 (240)

A Review of automatic differentiation and its efficient implementation

, 2019
Derivatives play a critical role in computational statistics, examples being Bayesian inference using Hamiltonian Monte Carlo sampling and the training of neural networks.
Margossian, Charles C.
core   +1 more source

CPT: Pharmacometrics and Systems Pharmacology

CPT: Pharmacometrics & Systems Pharmacology, 2012
Welcome to the first issue of CPT: Pharmacometrics and Systems Pharmacology (CPT:PSP), a new journal from the American Society for Clinical Pharmacology and Therapeutics. CPT:PSP is a cross‐disciplinary journal devoted to publishing advances in quantitative, model‐based approaches as applied in pharmacology, (patho)physiology, and disease to aid the ...
openaire   +2 more sources

Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Semaglutide has previously been approved for weight management and cardiovascular disease as a subcutaneous formulation, and more recently also as an oral formulation. However, there is limited information across oral dose levels, and there are no studies for the 25 mg dose in people with obesity and type 2 diabetes (T2D).
Rune Viig Overgaard, Oscar Birkhan, Naveen Rathor, Thomas Sparsø, Anders Strathe, Sean Wharton, Domenica Rubino   +6 more
wiley   +1 more source

Pharmacokinetics of Moxidectin in Bare‐Nosed Wombats (Vombatus ursinus) After Intravenous, Sub‐Cutaneous and Transdermal Administration

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT The anti‐parasitic drug moxidectin is a frontline treatment for sarcoptic mange in bare‐nosed wombats (Vombatus ursinus), a disease causing significant animal welfare issues and instances of local population declines. Despite widespread usage, knowledge of species‐specific pharmacokinetics of moxidectin in bare‐nosed wombats is still limited ...
E. K. Stott, L. F. Skerratt, T. Whittem, M. Leeming, K. Pillay, G. S. Doran, B. Gardner, M. Lynch, M. Klein, P. Holz, T. Chen, J. Hufschmid, A. P. Woodward   +12 more
wiley   +1 more source

Leveraging quantitative systems pharmacology modeling for elranatamab regimen optimization in relapsed or refractory multiple myeloma

npj Systems Biology and Applications
Elranatamab, an approved bispecific antibody (BsAb) for relapsed/refractory multiple myeloma, forms an immune synapse between the T-cell CD3 marker and B-cell maturation antigen (BCMA) on myeloma cells. Circulating soluble BCMA (sBCMA) is associated with
Kamrine E. Poels, Mohamed Elmeliegy, Jennifer Hibma, Diane Wang, Cynthia J. Musante, Blerta Shtylla   +5 more
doaj   +1 more source

A tutorial on pharmacometric Markov models

CPT: Pharmacometrics & Systems Pharmacology
AbstractThe Markov chain is a stochastic process in which the future value of a variable is conditionally independent of the past, given its present value. Data with Markovian features are characterized by: frequent observations relative to the expected changes in values, many consecutive same‐category or similar‐value observations at the individual ...
Qing Xi Ooi, Elodie Plan, Martin Bergstrand   +2 more
openaire   +2 more sources

Safety, Pharmacokinetics, and Dose Recommendations for Nirmatrelvir/Ritonavir in Individuals with Mild to Moderate COVID‐19 and Severe Renal Impairment

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1604-1613, June 2026.
Patients with severe renal impairment and COVID‐19 are at high risk for severe disease and death. Nirmatrelvir/ritonavir, an antiviral therapy for COVID‐19, is eliminated by renal excretion and can accumulate in patients with severe renal impairment.
Jacqueline Gerhart, Candace R. Bramson, Michelle Goulding, Haihong Shi, Olayide Oladoyinbo, Phylinda L. S. Chan, Sunring Chime, Jennifer Hammond   +7 more
wiley   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Population Pharmacokinetics of the Novel Myeloperoxidase Inhibitor Mitiperstat

Pharmacology Research &Perspectives, Volume 14, Issue 3, June 2026.
ABSTRACT Mitiperstat is a novel myeloperoxidase inhibitor being investigated for the treatment of heart failure, metabolic dysfunction‐associated steatohepatitis, and chronic obstructive pulmonary disease. Pharmacokinetic data from five clinical trials were used to develop a mitiperstat population pharmacokinetics (popPK) model.
Mikael Sunnåker, Jacob Leander, Hans Ericsson   +2 more
wiley   +1 more source

Integrating Population Approaches With Physiologically Based Pharmacokinetic Models: A Novel Framework for Parameter Estimation

CPT: Pharmacometrics & Systems Pharmacology
Physiologically Based Pharmacokinetic (PBPK) modeling is a powerful tool in drug development that integrates drug‐specific information with physiological parameters to predict drug concentrations.
Donato Teutonico, David Marchionni, Marc Lavielle, Laurent Nguyen   +3 more
doaj   +1 more source